Protocol Ledger

NCT03491150 · Phase III · TERMINATED

An Open-Label Crenezumab Study in Participants With Alzheimer's Disease

Interventional Phase III clinical trial protocol NCT03491150 sponsored by Roche / Genentech in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-04-11 Enrollment: 149 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03491150
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)149 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03491150
Protocol FieldVerified Registry Value
NCT IdentifierNCT03491150
Consolidated Lead SponsorRoche / Genentech
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment149 participants (ACTUAL)
Registered Start Date2018-04-11
WhyStopped ClassificationLack of Efficacy / Futility

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03491150
Hospital Research SiteLocationSite Profile
UC Davis Comprehensive Cancer CenterSacramento, CAOpen Hospital Dossier ->
UCSF Medical Center and Helen Diller Cancer CenterSan Francisco, CAOpen Hospital Dossier ->
Yale Cancer Center and Smilow Cancer HospitalNew Haven, CTOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Roche / Genentech across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI